BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Meckbach, Diana ^a   Keim, Ulrike ^a   Richter, Sabina ^a   Leiter, Ulrike ^a   Eigentler, Thomas K ^a   Bauer, Jürgen ^a   Pflugfelder, Annette ^a   Büttner, Petra ^b   Garbe, Claus ^a,b   Weide, Benjamin ^a,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b JAMES COOK UNIVERSITY   (Australia)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DACARBAZINE; LACTATE DEHYDROGENASE; TEMOZOLOMIDE; ALKYLATING AGENT; BRAF PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIMARY HEALTH CARE; AGED; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SKIN NEOPLASMS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84895899980     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089218     Document Type: Article

References (22)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
2. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, et al. (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759. (Pubitemid 36231971)
3. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
6. Si L, Kong Y, Xu X, Flaherty KT, Sheng X, et al. (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48: 94-100.
7. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, et al. (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29: 1239-1246.
8. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, et al. (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18: 3242-3249.
9. Jakob JA, Bassett RL, Jr., Ng CS, Curry JL, Joseph RW, et al. (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118: 4014-4023.
10. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, et al. (2004) Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6.
11. von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, et al. (2012) First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 23: 531-536.
12. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, et al. (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16: 471-478. (Pubitemid 44934704)
13. Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, et al. (2013) BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. J Invest Dermatol 133: 509-517.
14. Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, et al. (2012) Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol 19: 4314-4321.
15. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, et al. (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17: 229-235.
16. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, et al. (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95: 1878-1890.
17. Shinozaki M, Fujimoto A, Morton DL, Hoon DS (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10: 1753-1757. (Pubitemid 38435567)
18. Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, et al. (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125: 312-317. (Pubitemid 41648165)
19. Lasithiotakis KG, Leiter U, Eigentler T, Breuninger H, Metzler G, et al. (2007) Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed? Cancer 109: 1174-1182. (Pubitemid 46435398)
20. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, et al. (2011) Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117: 1697-1703.
21. Bauer J, Buttner P, Murali R, Okamoto I, Kolaitis NA, et al. (2011) BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 24: 345-351.
22. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, et al. (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30: 2522-2529.